Keck School Faculty

Louis VanderMolen

Louis VanderMolen

Professor of Clinical Medicine
Vice Chair of Clinical Oncology, Orange County Program
520 Superior Avenue, Suite 300 Health Sciences Campus Newport Beach

Orange County Medical Association: Physician of Excellence Award, 2006-2013

Baylor College of Medicine: Chief Resident, Internal Medicine, 1983-1984

Phi Beta Kappa: Elected Member, 1977

Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm. 2012 Aug; 27(6):337-43.. View in PubMed

A retrospective study of induction chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil followed by concurrent radiotherapy with cetuximab in locally advanced head and neck cancer Am J Otolaryngol. 2012 Jan-Feb; 33(1):93-7. . View in PubMed

Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer? Cancer Biother Radiopharm. 2011 Jun; 26(3):273-7.. View in PubMed

High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants Am J Clin Oncol. 2005 Jun; 28(3):281-8. . View in PubMed

Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma Cancer Biother Radiopharm. 2004 Oct; 19(5):570-80. . View in PubMed

Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr; 26(2):141-5.. View in PubMed

Successful treatment of transitional cell carcinoma of the urethra with chemotherapy Cancer Invest. 2002; 20(2):206-7. . View in PubMed

Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma Cancer Biother Radiopharm. 2001 Feb; 16(1):47-54. . View in PubMed

Profile of the pediatric endocrine clinic at New York-Presbyterian Hospital, New York Weill Cornell Center J Clin Endocrinol Metab. 1999 Dec; 84(12):4444-9. . View in PubMed

Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the Cancer Biotherapy Research Group (formerly the National Biotherapy Study Group) Cancer Biother Radiopharm. 1997 Aug; 12(4):249-55. . View in PubMed

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer J Clin Oncol. 1996 Aug; 14(8):2234-41. . View in PubMed

Malignant melanoma and pregnancy ten questions West J Med. 1996 Feb; 164(2):156-61. . View in PubMed

The integration of high-dose chemotherapy and biotherapy: initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center Cancer Biother. 1995; 10(1):25-36. . View in PubMed

High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer J Clin Oncol. 1993 Nov; 11(11):2118-26. . View in PubMed

Primary lymphoma of the kidney: complete remission after systemic chemotherapy J Natl Cancer Inst. 1993 Mar 17; 85(6):505-6. . View in PubMed

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma J Natl Cancer Inst. 1992 Jun 17; 84(12):929-37. . View in PubMed

Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity J Clin Oncol. 1990 Oct; 8(10):1618-29. . View in PubMed

Surface light chain phenotype in indolent lymphomas: lack of prognostic significance Am J Hematol. 1990 May; 34(1):15-20. . View in PubMed

Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha Br J Haematol. 1990 May; 75(1):133-5. . View in PubMed

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial J Natl Cancer Inst. 1990 Apr 18; 82(8):697-703. . View in PubMed

Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma J Natl Cancer Inst. 1990 Feb 07; 82(3):235-8. . View in PubMed

Diffuse osteosclerosis in hairy cell leukemia Blood. 1989 Nov 01; 74(6):2066-9. . View in PubMed

Adrenal insufficiency and interleukin-2 therapy Ann Intern Med. 1989 Jul 15; 111(2):185. . View in PubMed

Hypothyroidism after interleukin-2 therapy J Clin Oncol. 1989 May; 7(5):686-7. . View in PubMed

Lactic acidosis in lymphoma: prompt resolution of acidosis with therapy directed at the lymphoma J Natl Cancer Inst. 1988 Sep 07; 80(13):1077-8. . View in PubMed

Ringed sideroblasts in primary myelodysplasiaLeukemic propensity and prognostic factors. Arch Intern Med. 1988 Mar; 148(3):653-6. . View in PubMed

Torsade de pointes: an unusual manifestation of chloral hydrate poisoning Am Heart J. 1986 Jul; 112(1):181-4. . View in PubMed

Plasma cell dyscrasia with marrow fibrosisClinicopathologic syndrome. Am J Med. 1985 Sep; 79(3):297-302. . View in PubMed

Multiple myeloma in a homosexual man with chronic lymphadenopathy Arch Intern Med. 1985 Apr; 145(4):745-6. . View in PubMed

Dr. VanderMolen earned his medical degree from Loyola University Stritch School of Medicine. He performed his Internal Medicine Internship and Residency from Baylor College of Medicine- Texas Medical Center. He then went on to complete two fellowships, the first in hematology at Baylor, and the second in oncology at National Cancer Institute- Clinical Oncology Program.
sc ctsi logoPowered by SC CTSI